# Evaluating the Pharmacokinetics and Pharmacodynamics of Romiplostim in Patients With Immune Thrombocytopenia (ITP)

> **NCT02868060** · PHASE1,PHASE2 · COMPLETED · sponsor: **Kyowa Kirin China Pharmaceutical Co., Ltd.** · enrollment: 16 (actual)

## Conditions studied

- Immune Thrombocytopenia (ITP)

## Interventions

- **DRUG:** Romiplostim

## Key facts

- **NCT ID:** NCT02868060
- **Lead sponsor:** Kyowa Kirin China Pharmaceutical Co., Ltd.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1,PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2015-09
- **Primary completion:** 2017-08
- **Final completion:** 2017-08
- **Target enrollment:** 16 (ACTUAL)
- **Last updated:** 2024-04-29


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02868060

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02868060, "Evaluating the Pharmacokinetics and Pharmacodynamics of Romiplostim in Patients With Immune Thrombocytopenia (ITP)". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT02868060. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*